Dergiler / Archives of Rheumatology / 2022 / Cilt: 37 - Sayı: 2

Evaluation of musculoskeletal adverse effects in patients on systemic isotretinoin treatment: A cross-sectional study

Sayfa
223–229
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Evaluation of the patients for musculoskeletal side effects during isotretinoin use is important in clinical practice, as it is a common occurrence.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: This study aims to investigate the frequency of musculoskeletal adverse effects in acne vulgaris patients receiving systemic isotretinoin treatment.
📊
Temel Bulgular & Veri:Patients and methods: Between January 2016 and December 2017, a total of 200 severe acne patients (22 males, 178 females; mean age: 21.8±0.4 years; range, 15 to 53 years) who were on isotretinoin treatment were retrospectively analyzed.
💡
Sonuç & Katkı:Evaluation of the patients for musculoskeletal side effects during isotretinoin use is important in clinical practice, as it is a common occurrence.
🔬Tür:Araştırma Makalesi
📍Kapsam:2016 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: This study aims to investigate the frequency of musculoskeletal adverse effects in acne vulgaris patients receiving systemic isotretinoin treatment. Patients and methods: Between January 2016 and December 2017, a total of 200 severe acne patients (22 males, 178 females; mean age: 21.8±0.4 years; range, 15 to 53 years) who were on isotretinoin treatment were retrospectively analyzed. Data including age, sex, body mass index (BMI), duration of disease, diagnosis, and comorbidities were recorded. Back pain severity was evaluated with the Visual Analog Scale (VAS). Results: The treatment period was mean 8.5±0.1 (range, 6 to 12) months. The dose of isotretinoin was mean 0.6±0.1 (range, 0.5 and 1) mg/kg. Musculoskeletal side effects were seen in 99 (49.5%) patients. Back pain was reported during the treatment period in 78 (78.7%) patients. The diagnosis was mechanical back pain in 31 (39.7%) and inflammatory back pain in 47 (60.3%) patients. The moderate-severe back pain group received higher cumulative isotretinoin doses than the mild back pain group (p=0.003). The BMI values did not show a significant difference between the patients with and without back pain (p=0.55). There was no significant correlation between the BMI and VAS scores (p=0.06). The VAS scores were found to be correlated with age (p=0.04). Sacroiliitis was diagnosed in four (4%) patients. One (1%) patient was diagnosed with enthesitis. Creatine kinase elevation was reported in 18 (18.1%) patients, while three (3%) patients described myalgia of mild severity. Conclusion: Low back pain is one of the most common musculoskeletal side effects of isotretinoin treatment that usually resolves with dose reduction. The cumulative dose of isotretinoin does not seem to play a role in the development of back pain, but can determine pain severity. Pain severity is directly correlated with the increasing age. Evaluation of the patients for musculoskeletal side effects during isotretinoin use is important in clinical practice, as it is a common occurrence.

🔖

Bu Makaleye Atıf Yap

ŞAŞ, S., KOÇAK, F. A., ACAR, E. M. (2022). Evaluation of musculoskeletal adverse effects in patients on systemic isotretinoin treatment: A cross-sectional study. Archives of Rheumatology, Cilt: 37 - Sayı: 2, 223–229. https://ajindex.com/articles/447955

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (17)

  1. Rigopoulos D, Larios G, Katsambas AD. The role of isotretinoin in acne therapy: Why not as first-line therapy? Facts and controversies. Clin Dermatol 2010;28:24-30
  2. Ott F, Bollag W, Geiger JM. Oral 9-cis-retinoic acid versus 13-cis-retinoic acid in acne therapy. Dermatology 1996;193:124-6
  3. Baykal Selçuk L, Aksu Arıca D, Baykal ahin H, Yaylı S, Bahadır S. The prevalence of sacroiliitis in patients with acne vulgaris using isotretinoin. Cutan Ocul Toxicol 2017;36:176-9
  4. Alkan S, Kayiran N, Zengin O, Kalem A, Kimyon G, Kilinc EO, et al. Isotretinoin-induced spondyloarthropathy-related symptoms: A prospective study. J Rheumatol 2015;42:2106-9
  5. Lowenstein EB, Lowenstein EJ. Isotretinoin systemic therapy and the shadow cast upon dermatology's downtrodden hero. Clin Dermatol 2011;29:652-61
  6. Ganceviciene R, Zouboulis CC. Isotretinoin: State of the art treatment for acne vulgaris. J Dtsch Dermatol Ges 2010;8 Suppl 1:S47-59
  7. Kaplan G, Haettich B. Rheumatological symptoms due to retinoids. Baillieres Clin Rheumatol 1991;5:77-97
  8. Pedraz T, Martínez A, Pascual E. Acute hip monoarthritis in a patient treated with isotretinoin. J Clin Rheumatol 2006;12:105-6
  9. Nesher G, Zuckner J. Rheumatologic complications of vitamin A and retinoids. Semin Arthritis Rheum 1995;24:291-6
  10. Hughes RA. Arthritis precipitated by isotretinoin treatment for acne vulgaris. J Rheumatol 1993;20:1241-2
  11. Dinçer Ü, Çakar E, Kıralp MZ, Dursun H. Can isotretinoin induce sacroiliitis: Three cases. Romatizma 2008;23:157-9
  12. Bergler-Czop B, Brzezińska-Wcisło L. Proinflammatory cytokines in patients with various kinds of acne treated with isotretinoin. Postepy Dermatol Alergol 2014;31:21-8
  13. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: Role in arthritis. Front Biosci 2006;11:529-43
  14. Dalmolin RJ, Zanotto-Filho A, De Oliveira RB, Duarte RF, Pasquali MA, Moreira JC. Retinol and retinoic acid increase MMP-2 activity by different pathways in cultured Sertoli cells. Free Radic Res 2007;41:1338-47
  15. Sameem F, Semira. Isotretinoin-induced acute severe myopathy involving pelvic girdle muscles: A case report. Indian J Pharmacol 2016;48:601-3
  16. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004;14:395-403
  17. Taheri A, Sabouhi S, Farazmand F. Incidence of low back pain and sacroilii